USPTO serial 79420083
CKD
Reviewed by CopyMark Law Group
Status 681
- Filing date
- Status date
- Registration date
- —
- Examiner
- ROACH, APRIL K
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CKD?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alexis P. Grilli
Alexis P. Grilli Nixon Peabody LLP799 9th Street, NW, Suite 500Washington, DC 20001United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, targeted protein degrader for the treatment, prevention and alleviation of oncologic diseases; pharmaceuticals namely targeted protein degrader for the treatment, prevention and alleviation of oncologic diseases; medicines for human purposes namely, targeted protein degrader for the treatment, prevention and alleviation of oncologic diseases; target protein degrader namely, pharmaceutical preparations for the treatment, prevention and alleviation of oncologic diseases | ACTIVE | — |
| 040 | Custom manufacture of pharmaceuticals namely targeted protein degrader for the treatment, prevention and alleviation of oncologic diseases | ACTIVE | — |
| 042 | Testing, inspection or research of pharmaceuticals namely targeted protein degrader for the treatment, prevention and alleviation of oncologic diseases; consulting services in the field of testing, inspection or research of pharmaceuticals namely, targeted protein degrader for the treatment, prevention and alleviation of oncologic diseases; providing scientific information about medical testing of pharmaceuticals, and providing scientific testing, inspection and research information in the field of pharmaceuticals namely, targeted protein degrader for the treatment, prevention and alleviation of oncologic diseases; Medical and scientific research, namely, conducting clinical trials for others in the field of pharmaceuticals in the field of targeted protein degrader for the treatment, prevention and alleviation of oncologic diseases; research and development services in the field of pharmaceutical preparations namely, targeted protein degrader for the treatment, prevention and alleviation of oncologic diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Mitsubishi Tanabe Pharma Corporation
- Other trademarks owned by Tanabe Pharma Corporation
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named CKD
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 4, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 13, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 10, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 9, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 9, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 9, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 26, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 26, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Apr 2, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 12, 2026 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Mar 9, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 9, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 9, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 17, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 17, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 17, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 5, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 17, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 17, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 10, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 9, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 8, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 30, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 30, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 27, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |